Skip to main content
SpringerLink
Log in

Hemodialysis Infectious Complications

  • Chapter
  • First Online:
Complications in Dialysis

  • 257 Accesses

Abstract

The hemodialysis procedure places patients at risk of acquiring infections. Studies have repeatedly demonstrated that infections can be prevented in the hemodialysis setting. We will discuss prevention of infections and infectious complications with a particular emphasis on the role of infection prevention for vascular access-related, bloodborne, respiratory infections, and hemodialysis water systems. Innovation and research are needed to continue to advance patient safety in infection prevention and control in hemodialysis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. National Institute of Diabetes and Digestive and Kidney Diseases. United States Renal Data System, 2021 USRDS annual data report: epidemiology of kidney disease in the United States. Bethesda: National Institutes of Health; 2021.

    Google Scholar 

  2. Nguyen DB, Bixler D, Patel PR. Transmission of hepatitis C virus in the dialysis setting and strategies for its prevention. Semin Dial. 2019;32(2):127–34.

    Article  PubMed  Google Scholar 

  3. Centers for Disease Control and Prevention. Dialysis-related outbreaks: current. 2022. https://www.cdc.gov/dialysis/reports-news/outbreaks.html. Accessed 10 Nov 2022.

  4. Syed-Ahmed M, Narayanan M. Immune dysfunction and risk of infection in chronic kidney disease. Adv Chronic Kidney Dis. 2019;26(1):8–15.

    Article  PubMed  Google Scholar 

  5. Vanholder R, Ringoir S. Polymorphonuclear cell function and infection in dialysis. Kidney Int Suppl. 1992;38:S91–5.

    CAS  PubMed  Google Scholar 

  6. Prevention, C.f.D.C.a. Healthcare-Associated Hepatitis B and C Outbreaks (≥2 cases) reported to the CDC 2008–2018. https://www.cdc.gov/hepatitis/outbreaks/healthcarehepoutbreaktable.htm. Accessed 31 Dec 2019.

  7. Patel PR, Brinsley-Rainisch K. The making dialysis safer for patients coalition: a new partnership to prevent hemodialysis-related infections. Clin J Am Soc Nephrol. 2017;13(1):175–81.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Patel PR, Tanz LJ, Hamilton E, Swanzy K, et al. Assessment of provision of COVID-19 vaccination in dialysis clinics and patient vaccination coverage. JAMA Intern Med. 2022;182(6):676–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Silberzweig J, Bhat JG, Dittrich MO, Durvasula R, et al. Collaboration between dialysis providers. J Am Soc Nephrol. 2022;33(8):1440–4.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Favero MS, Carson LA, Bond WW, Petersen NJ. Pseudomonas aeruginosa: growth in distilled water from hospitals. Science. 1971;173(999):836–8.

    Article  CAS  PubMed  Google Scholar 

  11. Novosad SA, Lake J, Nguyen D, Soda E, et al. Multicenter outbreak of Gram-negative bloodstream infections in hemodialysis patients. Am J Kidney Dis. 2019;74(5):610–9.

    Article  CAS  PubMed  Google Scholar 

  12. Centers for Disease Control and Prevention. Core Interventions. https://www.cdc.gov/dialysis/prevention-tools/core-interventions.html. Accessed 5 Nov 2020

  13. Centers for Disease Control and Prevention. Audit tools and checklists. https://www.cdc.gov/dialysis/prevention-tools/audit-tools.html. Accessed 31 Dec 2019.

  14. Sehulster L, Chinn RY. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep. 2003;52(RR-10):1–42.

    PubMed  Google Scholar 

  15. Lettau LA, Alfred HJ, Glew RH, Fields HA, et al. Nosocomial transmission of delta hepatitis. Ann Intern Med. 1986;104(5):631–5.

    Article  CAS  PubMed  Google Scholar 

  16. Grohskopf LA, Roth VR, Feikin DR, Arduino MJ, et al. Serratia liquefaciens bloodstream infections from contamination of epoetin alfa at a hemodialysis center. N Engl J Med. 2001;344(20):1491–7.

    Article  CAS  PubMed  Google Scholar 

  17. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50(RR-5):1–43.

    Google Scholar 

  18. Kumbar L, Yee J. Current concepts in hemodialysis vascular access infections. Adv Chronic Kidney Dis. 2019;26(1):16–22.

    Article  PubMed  Google Scholar 

  19. Oyong K, Marquez P, Terashita D, English L, et al. Outbreak of bloodstream infections associated with multiuse dialyzers containing O-rings. Infect Control Hosp Epidemiol. 2014;35(1):89–91.

    Article  PubMed  Google Scholar 

  20. Centers for Disease Control and Prevention. Tracking infections in outpatient dialysis facilities. https://www.cdc.gov/nhsn/dialysis/index.html. Accessed 31 Dec 2019.

  21. Services, C.f.M.M. ESRD Quality Incentive Program. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/ESRDQIP/index. Accessed 31 Dec 2019.

  22. Centers for Disease Control and Prevention. Dialysis event surveillance protocol. https://www.cdc.gov/nhsn/PDFs/pscManual/8pscDialysisEventcurrent.pdf. Accessed 31 Dec 2019.

  23. Nguyen DB, Shugart A, Lines C, Shah AB, et al. National Healthcare Safety Network (NHSN) dialysis event surveillance report for 2014. Clin J Am Soc Nephrol. 2017;12(7):1139–46.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Klevens RM, Edwards JR, Andrus ML, Peterson KD, et al. Dialysis surveillance report: National Healthcare Safety Network (NHSN)-data summary for 2006. Semin Dial. 2008;21(1):24–8.

    Article  PubMed  Google Scholar 

  25. Klevens RM, Tokars JI, Andrus M. Electronic reporting of infections associated with hemodialysis. Nephrol News Issues. 2005;19(7):37–8.

    PubMed  Google Scholar 

  26. Centers for Disease Control and Prevention. Surveillance summary of Bloodstream Infections (BSI) in outpatient hemodialysis facilities. National Healthcare Safety Network, 2014–2019. https://www.cdc.gov/dialysis/published-studies/index.html.

  27. Lok CE, Sontrop JM, Tomlinson G, Rajan D, et al. Cumulative patency of contemporary fistulas versus grafts (2000–2010). Clin J Am Soc Nephrol. 2013;8(5):810–8.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Lee T. Fistula first initiative: historical impact on vascular access practice patterns and influence on future vascular access care. Cardiovasc Eng Technol. 2017;8(3):244–54.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Allon M, Dinwiddie L, Lacson E Jr, Latos DL, et al. Medicare reimbursement policies and hemodialysis vascular access outcomes: a need for change. J Am Soc Nephrol. 2011;22(3):426–30.

    Article  PubMed  Google Scholar 

  30. Brown RS. Barriers to optimal vascular access for hemodialysis. Semin Dial. 2020;33(6):457–63.

    Article  PubMed  Google Scholar 

  31. Murea M, Grey CR, Lok CE. Shared decision-making in hemodialysis vascular access practice. Kidney Int. 2021;100(4):799–808.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Lok CE, Huber TS, Lee T, Shenoy S, et al. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis. 2020;75(4 Suppl 2):S1–S164.

    Article  PubMed  Google Scholar 

  33. Patel PR, Yi SH, Booth S, Bren V, et al. Bloodstream infection rates in outpatient hemodialysis facilities participating in a collaborative prevention effort: a quality improvement report. Am J Kidney Dis. 2013;62(2):322–30.

    Article  PubMed  Google Scholar 

  34. Yi SH, Kallen AJ, Hess S, Bren VR, et al. Sustained infection reduction in outpatient hemodialysis centers participating in a collaborative bloodstream infection prevention effort. Infect Control Hosp Epidemiol. 2016;37(7):863–6.

    Article  PubMed  Google Scholar 

  35. Rosenblum A, Wang W, Ball LK, Latham C, et al. Hemodialysis catheter care strategies: a cluster-randomized quality improvement initiative. Am J Kidney Dis. 2014;63(2):259–67.

    Article  PubMed  Google Scholar 

  36. Centers for Disease Control and Prevention. Infection prevention tools. https://www.cdc.gov/dialysis/prevention-tools/index.html. Accessed 31 Dec 2019.

  37. McAfee N, Seidel K, Watkins S, Flynn JT. A continuous quality improvement project to decrease hemodialysis catheter infections in pediatric patients: use of a closed luer-lock access cap. Nephrol Nurs J. 2010;37(5):541–4.

    PubMed  Google Scholar 

  38. Brunelli SM, Njord L, Hunt AE, Sibbel SP. Use of the Tego needlefree connector is associated with reduced incidence of catheter-related bloodstream infections in hemodialysis patients. Int J Nephrol Renovasc Dis. 2014;7:131–9.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Brunelli SM, Van Wyck DB, Njord L, Ziebol RJ, et al. Cluster-randomized trial of devices to prevent catheter-related bloodstream infection. J Am Soc Nephrol. 2018;29(4):1336–43.

    Article  PubMed  PubMed Central  Google Scholar 

  40. O'Grady NP, Alexander M, Burns LA, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis. 2011;52(9):e162–93.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Buetti N, Marschall J, Drees M, Fakih MG, et al. Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 update. Infect Control Hosp Epidemiol. 2022;43(5):553–69.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Fernandez-Hidalgo N, Almirante B. Antibiotic-lock therapy: a clinical viewpoint. Expert Rev Anti-Infect Ther. 2014;12(1):117–29.

    Article  CAS  PubMed  Google Scholar 

  43. Landry DL, Braden GL, Gobeille SL, Haessler SD, et al. Emergence of gentamicin-resistant bacteremia in hemodialysis patients receiving gentamicin lock catheter prophylaxis. Clin J Am Soc Nephrol. 2010;5(10):1799–804.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Moore CL, Besarab A, Ajluni M, Soi V, et al. Comparative effectiveness of two catheter locking solutions to reduce catheter-related bloodstream infection in hemodialysis patients. Clin J Am Soc Nephrol. 2014;9(7):1232–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Maki DG, Ash SR, Winger RK, Lavin P. A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi-center, controlled, randomized trial. Crit Care Med. 2011;39(4):613–20.

    Article  CAS  PubMed  Google Scholar 

  46. Zhao T, Liu H, Han J. Ethanol lock is effective on reducing the incidence of tunneled catheter-related bloodstream infections in hemodialysis patients: a systematic review and meta-analysis. Int Urol Nephrol. 2018;50(9):1643–52.

    Article  CAS  PubMed  Google Scholar 

  47. Murray EC, Deighan C, Geddes C, Thomson PC. Taurolidine-citrate-heparin catheter lock solution reduces Staphylococcal bacteraemia rates in haemodialysis patients. QJM. 2014;107(12):995–1000.

    Article  CAS  PubMed  Google Scholar 

  48. Winnicki W, Herkner H, Lorenz M, Handisurya A, et al. Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters. Kidney Int. 2018;93(3):753–60.

    Article  CAS  PubMed  Google Scholar 

  49. Mermel LA, Alang N. Adverse effects associated with ethanol catheter lock solutions: a systematic review. J Antimicrob Chemother. 2014;69(10):2611–9.

    Article  CAS  PubMed  Google Scholar 

  50. Arechabala MC, Catoni MI, Claro JC, Rojas NP, et al. Antimicrobial lock solutions for preventing catheter-related infections in haemodialysis. Cochrane Database Syst Rev. 2018;4:Cd010597.

    PubMed  Google Scholar 

  51. Centers for Disease Control and Prevention. Updated recommendations on the use of chlorhexidine-impregnated dressings for prevention of intravascular catheter-related infections. 2017. https://www.cdc.gov/infectioncontrol/guidelines/bsi/c-i-dressings/recommendations.html. Accessed 31 Dec 2019.

  52. Apata IW, Hanfelt J, Bailey JL, Niyyar VD. Chlorhexidine-impregnated transparent dressings decrease catheter-related infections in hemodialysis patients: a quality improvement project. J Vasc Access. 2017;18(2):103–8.

    Article  PubMed  Google Scholar 

  53. Camins BC, Richmond AM, Dyer KL, Zimmerman HN, et al. A crossover intervention trial evaluating the efficacy of a chlorhexidine-impregnated sponge in reducing catheter-related bloodstream infections among patients undergoing hemodialysis. Infect Control Hosp Epidemiol. 2010;31(11):1118–23.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Onder AM, Chandar J, Coakley S, Francoeur D, et al. Controlling exit site infections: does it decrease the incidence of catheter-related bacteremia in children on chronic hemodialysis? Hemodial Int. 2009;13(1):11–8.

    Article  PubMed  Google Scholar 

  55. Righetti M, Palmieri N, Bracchi O, Prencipe M, et al. Tegaderm CHG dressing significantly improves catheter-related infection rate in hemodialysis patients. J Vasc Access. 2016;17(5):417–22.

    Article  PubMed  Google Scholar 

  56. Lyman M, Nguyen DB, Shugart A, Gruhler H, et al. Risk of vascular access infection associated with buttonhole cannulation of fistulas: data from the National Healthcare Safety Network. Am J Kidney Dis. 2020;76(1):82–9.

    Article  PubMed  PubMed Central  Google Scholar 

  57. DeSilva RN, Patibandla BK, Vin Y, Narra A, et al. Fistula first is not always the best strategy for the elderly. J Am Soc Nephrol. 2013;24(8):1297–304.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Woo K, Goldman DP, Romley JA. Early failure of dialysis access among the elderly in the era of fistula first. Clin J Am Soc Nephrol. 2015;10(10):1791–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Siegel JD, Rhinehart E, Jackson M, Chiarello L, et al. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control. 2007;35(10 Suppl 2):S165–93.

    Article  PubMed  Google Scholar 

  60. Uttley AH, George RC, Naidoo J, Woodford N, et al. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect. 1989;103(1):173–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Zacharioudakis IM, Zervou FN, Ziakas PD, Rice LB, et al. Vancomycin-resistant enterococci colonization among dialysis patients: a meta-analysis of prevalence, risk factors, and significance. Am J Kidney Dis. 2015;65(1):88–97.

    Article  CAS  PubMed  Google Scholar 

  62. Fishbane S, Cunha BA, Mittal SK, Ruggian J, et al. Vancomycin-resistant enterococci in hemodialysis patients is related to intravenous vancomycin use. Infect Control Hosp Epidemiol. 1999;20(7):461–2.

    Article  CAS  PubMed  Google Scholar 

  63. D'Agata EM, Green WK, Schulman G, Li H, et al. Vancomycin-resistant enterococci among chronic hemodialysis patients: a prospective study of acquisition. Clin Infect Dis. 2001;32(1):23–9.

    Article  CAS  PubMed  Google Scholar 

  64. St. Peter WL, S.C. Outpatient IV antibiotic use in the U.S. hemodialysis population, 1995–2007.

    Google Scholar 

  65. Dopirak M, Hill C, Oleksiw M, Dumigan D, et al. Surveillance of hemodialysis-associated primary bloodstream infections: the experience of ten hospital-based centers. Infect Control Hosp Epidemiol. 2002;23(12):721–4.

    Article  PubMed  Google Scholar 

  66. Taylor G, Gravel D, Johnston L, Embil J, et al. Prospective surveillance for primary bloodstream infections occurring in Canadian hemodialysis units. Infect Control Hosp Epidemiol. 2002;23(12):716–20.

    Article  PubMed  Google Scholar 

  67. Tokars JI, Miller ER, Stein G. New national surveillance system for hemodialysis-associated infections: initial results. Am J Infect Control. 2002;30(5):288–95.

    Article  PubMed  Google Scholar 

  68. Chang S, Sievert DM, Hageman JC, Boulton ML, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003;348(14):1342–7.

    Article  PubMed  Google Scholar 

  69. Finks J, Wells E, Dycke T, Husain N, et al. Vancomycin-resistant Staphylococcus aureus, Michigan, USA, 2007. Emerg Infect Dis. 2009;15(6):943–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Sievert DM, Rudrik JT, Patel JB, McDonald LC, et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002–2006. Clin Infect Dis. 2008;46(5):668–74.

    Article  CAS  PubMed  Google Scholar 

  71. Walters MS, Eggers P, Albrecht V, Travis T, et al. Vancomycin-resistant Staphylococcus aureus—Delaware, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(37):1056.

    Article  PubMed  Google Scholar 

  72. Centers for Disease Control and Prevention. CDC Reminds Clinical Laboratories and Healthcare Infection Preventionists of their Role in the Search and Containment of Vancomycin-Resistant Staphylococcus aureus (VRSA). 2022. https://www.cdc.gov/hai/settings/lab/vrsa_lab_search_containment.html#:~:text=The%20Centers%20for%20Disease%20Control%20and%20Prevention%20%28CDC%29,case%20identified%20in%20the%20United%20States%20in%202021. Accessed 22 Dec 2022.

  73. Walters M, Lonsway D, Rasheed K, Albrecht V, et al. Investigation and control of vancomycin-resistant Staphylococcus aureus: a guide for health departments and infection control personnel. CDC; 2015. https://www.cdc.gov/hai/pdfs/vrsa-investigation-guide-05_12_2015.pdf

    Google Scholar 

  74. Tokars JI, Miller E, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 1995. Altanta: US Department of Health and Human Services; 1998.

    Book  Google Scholar 

  75. Finelli L, Miller JT, Tokars JI, Alter MJ, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18(1):52–61.

    Article  PubMed  Google Scholar 

  76. Fluck R, Rao R, van Schalkwyk D, Ansell D, et al. The UK Vascular Access Survey—follow-up data and repeat survey (chapter 5). Nephrol Dial Transplant. 2007;22(Suppl 7):751–7.

    Google Scholar 

  77. Prevention, C.f.D.C.a. Healthcare-Associated Infections-Community Interface (HAIC): Emerging Infections Program (EIP) Network Report Invasive Staphylococcus aureus. 2016. https://www.cdc.gov/hai/eip/pdf/2016-MRSA-Report-508.pdf. Accessed 31 Dec 2019.

  78. Phatharacharukul P, Thongprayoon C, Cheungpasitporn W, Edmonds PJ, et al. The risks of incident and recurrent Clostridium difficile-associated diarrhea in chronic kidney disease and end-stage kidney disease patients: a systematic review and meta-analysis. Dig Dis Sci. 2015;60(10):2913–22.

    Article  PubMed  Google Scholar 

  79. Thongprayoon C, Cheungpasitporn W, Phatharacharukul P, Mahaparn P, et al. High mortality risk in chronic kidney disease and end stage kidney disease patients with Clostridium difficile infection: a systematic review and meta-analysis. J Nat Sci. 2015;1(4):e85.

    PubMed  PubMed Central  Google Scholar 

  80. Wetmore JB, Li S, Molony JT, Guo H, et al. Insights from the 2016 peer kidney care initiative report: still a ways to go to improve care for dialysis patients. Am J Kidney Dis. 2018;71(1):123–32.

    Article  PubMed  Google Scholar 

  81. Keddis MT, Khanna S, Noheria A, Baddour LM, et al. Clostridium difficile infection in patients with chronic kidney disease. Mayo Clin Proc. 2012;87(11):1046–53.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Evans R, Caskey F, Fluck R, Crowley L, et al. UK Renal Registry 18th annual Report: chapter 12 epidemiology of reported infections amongst patients receiving dialysis for established renal failure in England 2013 to 2014: a Joint Report from Public Health England and the UK Renal Registry. Nephron. 2016;132(Suppl 1):279–88.

    Article  PubMed  Google Scholar 

  83. See I, Bagchi S, Booth S, Scholz D, et al. Outbreak of Clostridium difficile infections at an outpatient hemodialysis facility-Michigan, 2012–2013. Infect Control Hosp Epidemiol. 2015;36(8):972–4.

    Article  PubMed  PubMed Central  Google Scholar 

  84. D'Agata EMC, Apata IW, Booth S, Boyce JM, et al. Suggestions for the prevention of Clostridioides difficile spread within outpatient hemodialysis facilities. Kidney Int. 2021;99(5):1045–53.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Pop-Vicas A, Strom J, Stanley K, D'Agata EM. Multidrug-resistant Gram-negative bacteria among patients who require chronic hemodialysis. Clin J Am Soc Nephrol. 2008;3(3):752–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Vallabhaneni S, Kallen A, Tsay S, Chow N, et al. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus-United States, May 2013–August 2016. MMWR Morb Mortal Wkly Rep. 2016;65(44):1234–7.

    Article  PubMed  Google Scholar 

  87. Centers for Disease Control and Prevention. Infection prevention and control for Candida auris. https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Ffungal%2Fdiseases%2Fcandidiasis%2Fc-auris-infection-control.html. Accessed 31 Dec 2019.

  88. Centers for Disease Control and Prevention. Core elements of antibiotic stewardship. https://www.cdc.gov/antibiotic-use/core-elements/index.html. Accessed 22 Dec 2022.

  89. Snyder GM, Patel PR, Kallen AJ, Strom JA, et al. Antimicrobial use in outpatient hemodialysis units. Infect Control Hosp Epidemiol. 2013;34(4):349–57.

    Article  PubMed  Google Scholar 

  90. D'Agata EM. Antimicrobial use and stewardship programs among dialysis centers. Semin Dial. 2013;26(4):457–64.

    Article  PubMed  Google Scholar 

  91. Apata IW, Kabbani S, Neu AM, Kear TM, et al. Opportunities to improve antibiotic prescribing in outpatient hemodialysis facilities. Am J Kidney Dis. 2020;77(5):757–68.

    Article  PubMed  Google Scholar 

  92. Favero MS, Maynard JE, Petersen NJ, Boyer KM, et al. Letter: Hepatitis-B antigen on environmental surfaces. Lancet. 1973;2(7843):1455.

    Article  CAS  PubMed  Google Scholar 

  93. Centers for Disease Control and Prevention. In: H.E.A. Welfare, editor. Control measures for hepatitis B in dialysis centers. Atlanta: Centers for Disease Control; 1977.

    Google Scholar 

  94. Alter MJ, Favero MS, Francis DP. Cost benefit of vaccination for hepatitis B in hemodialysis centers. J Infect Dis. 1983;148(4):770–1.

    Article  CAS  PubMed  Google Scholar 

  95. Alter MJ, Favero MS, Maynard JE. Impact of infection control strategies on the incidence of dialysis-associated hepatitis in the United States. J Infect Dis. 1986;153(6):1149–51.

    Article  CAS  PubMed  Google Scholar 

  96. Centers for Disease Control and Prevention. Viral hepatitis surveillance—United States. https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm. Accessed 31 Dec 2019.

  97. Tokars JI, Alter MJ, Miller E, Moyer LA, et al. National surveillance of dialysis associated diseases in the United States—1994. ASAIO J. 1997;43(1):108–19.

    CAS  PubMed  Google Scholar 

  98. Mast EE, Margolis HS, Fiore AE, Brink EW, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54(RR-16):1–31.

    PubMed  Google Scholar 

  99. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR-16):1–33.

    PubMed  Google Scholar 

  100. Rhea S, Moorman A, Pace R, Mobley V, et al. Hepatitis B reverse seroconversion and transmission in a hemodialysis center: a public health investigation and case report. Am J Kidney Dis. 2016;68(2):292–5.

    Article  PubMed  Google Scholar 

  101. Apata IW, Nguyen DB, Khudyakov Y, Mixson-Hayden T, et al. Hepatitis B virus mutant infections in hemodialysis patients: a case series. Kidney Med. 2019;1(6):347–53.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Hendrickson B, Kamili S, Timmons T, Iwen PC, et al. Notes from the field: false-negative hepatitis B surface antigen test results in a hemodialysis patient-Nebraska, 2017. MMWR Morb Mortal Wkly Rep. 2018;67(10):311–2.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Hoofnagle JH, Di Bisceglie AM. Serologic diagnosis of a cute and chronic hepatitis. Semin Liver Dis. 1991;11(2):73–83.

    Article  CAS  PubMed  Google Scholar 

  104. Hochberger S, Althof D, Gallegos de Schrott R, Nachbaur N, et al. Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol. 2006;35(4):373–80.

    Article  CAS  PubMed  Google Scholar 

  105. Kaneko S, Miller RH, Di Bisceglie A, Feinstone SM, et al. Hepatitis B virus DNA detection and comparison with hepatitis B surface antigen. Gastroenterol Jpn. 1990;25(Suppl 2):57–61.

    Article  PubMed  Google Scholar 

  106. Levine OS, Vlahov D, Koehler J, Cohn S, et al. Seroepidemiology of hepatitis B virus in a population of injecting drug users. Association with drug injection patterns. Am J Epidemiol. 1995;142(3):331–41.

    Article  CAS  PubMed  Google Scholar 

  107. Mezzelani P, Quaglio G, Venturini L, Lugoboni F. The significance of the isolated anti-HBc carrier. A study of 1797 drug addicts. The Intersert Group of Scientific Collaboration. Recenti Prog Med. 1994;85(9):419–24.

    CAS  PubMed  Google Scholar 

  108. Bhatti FA, Ullah Z, Salamat N, Ayub M, et al. Anti-hepatitis B core antigen testing, viral markers, and occult hepatitis B virus infection in Pakistani blood donors: implications for transfusion practice. Transfusion. 2007;47(1):74–9.

    Article  PubMed  Google Scholar 

  109. Satake M, Taira R, Yugi H, Hino S, et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion. 2007;47(7):1197–205.

    Article  PubMed  Google Scholar 

  110. Silva AE, McMahon BJ, Parkinson AJ, Sjogren MH, et al. Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. Clin Infect Dis. 1998;26(4):895–7.

    Article  CAS  PubMed  Google Scholar 

  111. Nieto JM, Saab SJCHR. Outcomes of liver transplantation using hepatitis B core-positive liver grafts: implications for prophylaxis. Curr Hepatitis Rep. 2006;5(1):33–9.

    Article  Google Scholar 

  112. McMahon BJ, Parkinson AJ, Helminiak C, Wainwright RB, et al. Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen. Gastroenterology. 1992;103(2):590–4.

    Article  CAS  PubMed  Google Scholar 

  113. Lai CL, Lau JY, Yeoh EK, Chang WK, et al. Significance of isolated anti-HBc seropositivity by ELISA: implications and the role of radioimmunoassay. J Med Virol. 1992;36(3):180–3.

    Article  CAS  PubMed  Google Scholar 

  114. Alter MJ, Ahtone J, Maynard JE. Hepatitis B virus transmission associated with a multiple-dose vial in a hemodialysis unit. Ann Intern Med. 1983;99(3):330–3.

    Article  CAS  PubMed  Google Scholar 

  115. Carl M, Francis DP, Maynard JE. A common-source outbreak of hepatitis bin a hemodialysis unit. Dial Transplant. 1983;12:222–9.

    Google Scholar 

  116. Centers for Disease Control and Prevention. Outbreaks of hepatitis B virus infection among hemodialysis patients—California, Nebraska, and Texas, 1994. MMWR Morb Mortal Wkly Rep. 1996;45(14):285–9.

    Google Scholar 

  117. Fabrizi F, Dixit V, Messa P, Martin P. Transmission of hepatitis B virus in dialysis units: a systematic review of reports on outbreaks. Int J Artif Organs. 2015;38(1):1–7.

    Article  PubMed  Google Scholar 

  118. Hutin YJ, Goldstein ST, Varma JK, O'Dair JB, et al. An outbreak of hospital-acquired hepatitis B virus infection among patients receiving chronic hemodialysis. Infect Control Hosp Epidemiol. 1999;20(11):731–5.

    Article  CAS  PubMed  Google Scholar 

  119. Niu MT, Penberthy LT, Alter MJ, et al. Hemodialysis-associated hepatitis B: report of an outbreak. Dial Transplant. 1989;18:542–55.

    Google Scholar 

  120. Snydman DR, Bryan JA, London WT, Werner B, et al. Transmission of hepatitis B associated with hemodialysis: role of malfunction (blood leaks) in dialysis machines. J Infect Dis. 1976;134(6):562–70.

    Article  CAS  PubMed  Google Scholar 

  121. Snydman DR, Bryan JA, Macon EJ, Gregg MB. Hemodialysis-associated hepatitis: report of an epidemic with further evidence on mechanisms of transmission. Am J Epidemiol. 1976;104(5):563–70.

    Article  CAS  PubMed  Google Scholar 

  122. Schillie S, Murphy TV, Sawyer M, Ly K, et al. CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. MMWR Recomm Rep. 2013;62(Rr-10):1–19.

    PubMed  Google Scholar 

  123. Centers for Disease Control and Prevention. Infection control requirements for dialysis facilities and clarification regarding guidance on parenteral medication vials. MMWR Morb Mortal Wkly Rep. 2008;57(32):875–6.

    Google Scholar 

  124. Kamili S, Krawczynski K, McCaustland K, Li X, et al. Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. Infect Control Hosp Epidemiol. 2007;28(5):519–24.

    Article  PubMed  Google Scholar 

  125. Paintsil E, Binka M, Patel A, Lindenbach BD, et al. Hepatitis C virus maintains infectivity for weeks after drying on inanimate surfaces at room temperature: implications for risks of transmission. J Infect Dis. 2014;209(8):1205–11.

    Article  CAS  PubMed  Google Scholar 

  126. World Health Organization. Hepatitis C Fact Sheets. 2022. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Accessed 22 Dec 2022.

  127. Pol S, Parlati L, Jadoul M. Hepatitis C virus and the kidney. Nat Rev Nephrol. 2019;15(2):73–86.

    Article  PubMed  Google Scholar 

  128. Selvarajah S, Busch MP. Transfusion transmission of HCV, a long but successful road map to safety. Antivir Ther. 2012;17(7 Pt B):1423–9.

    Article  PubMed  PubMed Central  Google Scholar 

  129. Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis. 1997;1:559–68.

    Article  CAS  PubMed  Google Scholar 

  130. Goodkin DA, Bieber B, Jadoul M, Martin P, et al. Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis. Clin J Am Soc Nephrol. 2017;12(2):287–97.

    Article  PubMed  Google Scholar 

  131. Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65(6):2335–42.

    Article  PubMed  Google Scholar 

  132. Jadoul M, Bieber BA, Martin P, Akiba T, et al. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int. 2019;95(4):939–47.

    Article  PubMed  Google Scholar 

  133. Centers for Disease Control and Prevention. Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep. 2013;62(18):362–5.

    Google Scholar 

  134. Kidney Disease: Improving Global Outcomes Hepatitis C Work Group. KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl (2011). 2018;8(3):91–165.

    Article  Google Scholar 

  135. Shimokura G, Chai F, Weber DJ, Samsa GP, et al. Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients. Infect Control Hosp Epidemiol. 2011;32(5):415–24.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Centers for Disease Control and Prevention. CDC urging dialysis providers and facilities to assess and improve infection control practices to stop hepatitis C virus transmission in patients undergoing hemodialysis. https://emergency.cdc.gov/han/han00386.asp. Accessed 31 Dec 2019.

  137. Jadoul M, Labriola L, Gordon CE. HCV can and should be eliminated from dialysis units. Am J Kidney Dis. 2021;78(4):487–8.

    Article  PubMed  Google Scholar 

  138. Maduell F, Belmar L, Ugalde J, Laguno M, et al. Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia. Gastroenterol Hepatol. 2019;42(3):164–70.

    Article  PubMed  Google Scholar 

  139. Huang CF, Chiu YW, Yu ML. Patient-centered outreach treatment toward micro-elimination of hepatitis C virus infection in hemodialysis patients. Kidney Int. 2020;97(2):421.

    Article  PubMed  Google Scholar 

  140. Feld JJ, Ward JW. Key elements on the pathway to HCV elimination: lessons learned from the AASLD HCV Special Interest Group 2020. Hepatol Commun. 2021;5(6):911–22.

    Article  PubMed  PubMed Central  Google Scholar 

  141. Hu TH, Su WW, Yang CC, Yang CC, et al. Elimination of hepatitis C virus in a dialysis population: a collaborative care model in Taiwan. Am J Kidney Dis. 2021;78(4):511–519 e1.

    Article  PubMed  Google Scholar 

  142. Bhamidimarri KR, Martin P. Finally, safe and effective treatment options for hepatitis C in hemodialysis patients. J Hepatol. 2016;65(1):7–10.

    Article  PubMed  Google Scholar 

  143. Safety, N.T.D. Promoting infection prevention in dialysis facilities hepatitis C testing and monitoring algorithm. https://www.asn-online.org/g/blast/files/NCHHSTP_NTDS-HCV%20Subcommittee%20Algorithm_FINAL%2003.29.19.pdf. Accessed 31 Dec 2019.

  144. Kushner T, Serper M, Kaplan DE. Delta hepatitis within the veterans affairs medical system in the United States: prevalence, risk factors, and outcomes. J Hepatol. 2015;63(3):586–92.

    Article  PubMed  PubMed Central  Google Scholar 

  145. Chen H-Y, Shen D-T, Ji D-Z, Han P-C, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019;68(3):512–21.

    Article  CAS  PubMed  Google Scholar 

  146. Sawinski D, Forde KA, Locke JE, Cohen JB, et al. Race but not hepatitis C co-infection affects survival of HIV(+) individuals on dialysis in contemporary practice. Kidney Int. 2018;93(3):706–15.

    Article  PubMed  Google Scholar 

  147. El Sayed NM, Gomatos PJ, Beck-Sague CM, Dietrich U, et al. Epidemic transmission of human immunodeficiency virus in renal dialysis centers in Egypt. J Infect Dis. 2000;181(1):91–7.

    Article  PubMed  Google Scholar 

  148. Mashragi F, Bernstein RS, Al-Mazroa M, Al-Tawfiq JA, et al. HIV transmission at a Saudi Arabia hemodialysis unit. Clin Infect Dis. 2014;59(6):897–902.

    Article  PubMed  PubMed Central  Google Scholar 

  149. Velandia M, Fridkin SK, Cardenas V, Boshell J, et al. Transmission of HIV in dialysis centre. Lancet. 1995;345(8962):1417–22.

    Article  CAS  PubMed  Google Scholar 

  150. Centers for Disease Control and Prevention. HIV transmission in a dialysis center—Colombia, 1991–1993. MMWR Morb Mortal Wkly Rep. 1995;44(21):404–5.

    Google Scholar 

  151. Branson BM, Handsfield HH, Lampe MA, Janssen RS, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17.

    PubMed  Google Scholar 

  152. Archibald LK, Khoi NN, Jarvis WR, Reller LB, et al. Pyrogenic reactions in hemodialysis patients, Hanoi, Vietnam. Infect Control Hosp Epidemiol. 2006;27(4):424–6.

    Article  PubMed  Google Scholar 

  153. Beck-Sague CM, Jarvis WR, Bland LA, Arduino MJ, et al. Outbreak of Gram-negative bacteremia and pyrogenic reactions in a hemodialysis center. Am J Nephrol. 1990;10(5):397–403.

    Article  CAS  PubMed  Google Scholar 

  154. Favero MS, Petersen NJ, Carson LA, Bond WW, et al. Gram-negative water bacteria in hemodialysis systems. Health Lab Sci. 1975;12(4):321–34.

    CAS  PubMed  Google Scholar 

  155. Gordon SM, Tipple M, Bland LA, Jarvis WR. Pyrogenic reactions associated with the reuse of disposable hollow-fiber hemodialyzers. JAMA. 1988;260(14):2077–81.

    Article  CAS  PubMed  Google Scholar 

  156. Hindman SH, Favero MS, Carson LA, Petersen NJ, et al. Pyrogenic reactions during haemodialysis caused by extramural endotoxin. Lancet. 1975;2(7938):732–4.

    Article  CAS  PubMed  Google Scholar 

  157. Jackson BM, Beck-Sague CM, Bland LA, Arduino MJ, et al. Outbreak of pyrogenic reactions and Gram-negative bacteremia in a hemodialysis center. Am J Nephrol. 1994;14(2):85–9.

    Article  CAS  PubMed  Google Scholar 

  158. Lefton CK. Patients suffer pyrogenic reactions in Philadelphia dialysis units. Nephrol News Issues. 1994;8(12):10.

    CAS  PubMed  Google Scholar 

  159. Nystrand R. The microbial world and fluids in dialysis. Biomed Instrum Technol. 2008;42(2):150–9.

    Article  PubMed  Google Scholar 

  160. Petersen NJ, Carson LA, Favero MS. Bacterial endotoxin in new and reused hemodialyzers: a potential cause of endotoxemia. Trans Am Soc Artif Intern Organs. 1981;27:155–60.

    CAS  PubMed  Google Scholar 

  161. Pollak VE. Adverse effects and pyrogenic reactions during hemodialysis. JAMA. 1988;260(14):2106–7.

    Article  CAS  PubMed  Google Scholar 

  162. Raij L, Shapiro FL, Michael AF. Endotoxemia in febrile reactions during hemodialysis. Kidney Int. 1973;4(1):57–60.

    Article  CAS  PubMed  Google Scholar 

  163. Rudnick JR, Arduino MJ, Bland LA, Cusick L, et al. An outbreak of pyrogenic reactions in chronic hemodialysis patients associated with hemodialyzer reuse. Artif Organs. 1995;19(4):289–94.

    Article  CAS  PubMed  Google Scholar 

  164. Favero MS, Bland LA. Microbiologic principles applied to reprocessing hemodialyzers. In: Deane N, Wineman R, Bemis J, editors. Guide to reprocessing of hemodialyzers. Boston: Martinus Nijhoff; 1986. p. 63–73.

    Chapter  Google Scholar 

  165. Favero MS, Carson LA, Bond WW, Petersen NJ. Factors that influence microbial contamination of fluids associated with hemodialysis machines. Appl Microbiol. 1974;28(5):822–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  166. AAMI. Preparation and quality management of fluids for haemodialysis and related therapies—part 1: general requirements. Association for the Advancment of Medical Instrumentation; 2019.

    Google Scholar 

  167. AAMI. Preparation and quality management of fluids for haemodialysis and related therapies—part 3: water for haemodialysis related therapies. Association for the Advancment of Medical Instrumentation; 2019.

    Google Scholar 

  168. AAMI. Preparation and quality management of fluids for haemodialysis and related therapies—part 5: quality of dialysis fluid for haemodialysis related therapies. Association for the Advancment of Medical Instrumentation; 2019.

    Google Scholar 

  169. Centers for Medicare and Medicaid Services. Medicare and Medicaid programs; conditions for coverage for end-stage renal disease facilities. Final rule. Fed Regist. 2008;73(73):20369–484.

    Google Scholar 

  170. Stamm JM, Engelhard WE, Parsons JE. Microbiological study of water-softener resins. Appl Microbiol. 1969;18:376–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  171. Desai N. Basics of base in hemodialysis solution: dialysate buffer production, delivery and decontamination. Indian J Nephrol. 2015;25(4):189–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  172. Anderson RL, Holland BW, Carr JK. Effect of disinfectants on pseudomonads colonized on the interior surfaces of PVC pipes. Am J Public Health. 1990;80:17–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  173. Centers for Disease Control and Prevention. Pyrogenic reactions and Gram-negative bacteremia in a hemodialysis center. In: H.a.H. Services, editor. Epidemiologic investigation report. Atlanta: Centers for Disease Control; 1991.

    Google Scholar 

  174. Jochimsen EM, Frenette C, Delorme M, Arduino M, et al. A cluster of bloodstream infections and pyrogenic reactions among hemodialysis patients traced to dialysis machine waste-handling option units. Am J Nephrol. 1998;18(6):485–9.

    Article  CAS  PubMed  Google Scholar 

  175. Petersen NJ, Boyer KM, Carson LA, Favero MS. Pyrogenic reactions from inadequate disinfection of a dialysis fluid distribution system. Dial Transplant. 1978;7:52–7.

    Google Scholar 

  176. Rao CY, Pachucki C, Cali S, Arduino M, et al. An outbreak of phialemonium mold infections in hemodialysis patients: when purified water is Not so Pure-Illinois, 2005. In: 55th Annual Epidemic Intelligence Service Conference. Atlanta: CDC; 2006.

    Google Scholar 

  177. Favero MS, Petersen NJ, Boyer KM, Carson LA, et al. Microbial contamination of renal dialysis systems and associated health risks. Trans Am Soc Artif Intern Organs. 1974;20A:175–83.

    CAS  PubMed  Google Scholar 

  178. Arduino MJ. Microbiologic quality of water used for hemodialysis. Contemp Dial Nephrol. 1996;17:17–9.

    Google Scholar 

  179. Wang SA, Levine RB, Carson LA, Arduino MJ, et al. An outbreak of Gram-negative bacteremia in hemodialysis patients traced to hemodialysis machine waste drain ports. Infect Control Hosp Epidemiol. 1999;20(11):746–51.

    Article  CAS  PubMed  Google Scholar 

  180. Backman L, Dumigan DG, Harizaj A, Oleksiw M, et al. A cluster of Gram-Negative bloodstream infections in connecticut hemodialysis patients. Washington, DC: IDWeek; 2019.

    Google Scholar 

  181. Centers for Disease Control and Prevention. Dialysis wall boxes and drains. https://www.cdc.gov/dialysis/guidelines/wall-boxes.html. Accessed 31 Dec 2019.

  182. AAMI. Water testing methodologies. Arlington: Association for the Advancement of Medical Instrumentation; 2014.

    Google Scholar 

  183. Arduino MJ. Heterotrophic plate count and endotoxin assay of hemodialysis fluids. In: Clinical microbiology procedures handbook. ASM Press; 2022.

    Google Scholar 

  184. Bland LA, Favero MS, editors. Microbial contamination control strategies for hemodialysis systems. Plant, technology, and safety management series, vol. 3. Oakbrook Terrace: Joint Commission on Accreditation of Healthcare Organizations; 1989.

    Google Scholar 

  185. Arduino MJ. What’s new in water treatment standards for hemodialysis. Contemp Dial Nephrol. 1997;18:21–4.

    Google Scholar 

  186. Petersen NJ, Carson LA, Doto IL, Aguero SM, et al. Microbiologic evaluation of a new glutaraldehyde-based disinfectant for hemodialysis systems. Trans Am Soc Artif Intern Organs. 1982;28:287–90.

    CAS  PubMed  Google Scholar 

  187. Townsend TR, Wee SB, Bartlett J. Disinfection of hemodialysis machines. Dial Transplant. 1985;14:274–87.

    Google Scholar 

  188. National Institute of Diabetes and Digestive and Kidney Diseases. United States Renal Data System, USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda: National Institutes of Health; 2008.

    Google Scholar 

  189. Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Kidney Int. 2006;70(6):1135–41.

    Article  CAS  PubMed  Google Scholar 

  190. Berman SJ, Johnson EW, Nakatsu C, Alkan M, et al. Burden of infection in patients with end-stage renal disease requiring long-term dialysis. Clin Infect Dis. 2004;39(12):1747–53.

    Article  PubMed  Google Scholar 

  191. Centers for Disease Control and Prevention. Pneumococcal ACIP Vaccine Recommendations. https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html. Accessed 23 Dec 2022.

  192. Centers for Disease Control and Prevention. Pneumococcal vaccination: summary of who and when to vaccinate. https://www.cdc.gov/vaccines/vpd/pneumo/hcp/who-when-to-vaccinate.html. Accessed 23 Dec 2022.

  193. Grohskopf LA, Sokolow LZ, Broder KR, Olsen SJ, et al. Prevention and control of seasonal influenza with vaccines. MMWR Recomm Rep. 2016;65(5):1–54.

    Article  PubMed  Google Scholar 

  194. Gilbertson DT, Unruh M, McBean AM, Kausz AT, et al. Influenza vaccine delivery and effectiveness in end-stage renal disease. Kidney Int. 2003;63(2):738–43.

    Article  PubMed  Google Scholar 

  195. Salgado CD, Giannetta ET, Hayden FG, Farr BM. Preventing nosocomial influenza by improving the vaccine acceptance rate of clinicians. Infect Control Hosp Epidemiol. 2004;25(11):923–8.

    Article  PubMed  Google Scholar 

  196. Saxen H, Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatr Infect Dis J. 1999;18(9):779–83.

    Article  CAS  PubMed  Google Scholar 

  197. Van Buynder PG, Konrad S, Kersteins F, Preston E, et al. Healthcare worker influenza immunization vaccinate or mask policy: strategies for cost effective implementation and subsequent reductions in staff absenteeism due to illness. Vaccine. 2015;33(13):1625–8.

    Article  PubMed  Google Scholar 

  198. Ventura CG, Roque FL, Sousa IQ, Lobo RD, et al. Influenza A (H1N1): outbreak management in a dialysis unit and clinical outcomes of infection in chronic hemodialysis patients. J Bras Nefrol. 2020;42(2):182–90.

    Article  PubMed  PubMed Central  Google Scholar 

  199. United States Renal Data System. Epidemiology of kidney disease in the United States. 2022. https://usrds-adr.niddk.nih.gov/2022/suggested-citation. Accessed 23 Dec 2022.

  200. Lynch JR, Armistead N, Vinson BB, Howard AD. Correlates of change in health care worker seasonal influenza vaccination rates among dialysis facilities. Am J Infect Control. 2015;43(4):409–11.

    Article  PubMed  Google Scholar 

  201. Segall L, Covic A. Diagnosis of tuberculosis in dialysis patients: current strategy. Clin J Am Soc Nephrol. 2010;5(6):1114–22.

    Article  CAS  PubMed  Google Scholar 

  202. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64(2):e1–e33.

    Article  PubMed  Google Scholar 

  203. Jensen PA, Lambert LA, Iademarco MF, Ridzon R, et al. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep. 2005;54(RR-17):1–141.

    PubMed  Google Scholar 

  204. Winthrop KL, Nyendak M, Calvet H, Oh P, et al. Interferon-gamma release assays for diagnosing mycobacterium tuberculosis infection in renal dialysis patients. Clin J Am Soc Nephrol. 2008;3(5):1357–63.

    Article  PubMed  PubMed Central  Google Scholar 

  205. Okada RC, Barry PM, Skarbinski J, Chitnis AS. Epidemiology, detection, and management of tuberculosis among end-stage renal disease patients. Infect Control Hosp Epidemiol. 2018;39(11):1367–74.

    Article  PubMed  Google Scholar 

  206. Centers for Disease Control and Prevention. Tuberculosis transmission in a renal dialysis center—Nevada, 2003. MMWR Morb Mortal Wkly Rep. 2004;53(37):873–5.

    Google Scholar 

  207. Alberici F, Delbarba E, Manenti C, Econimo L, et al. A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. Kidney Int. 2020;98(1):20–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  208. Khatri M, Islam S, Dutka P, Carson J, et al. COVID-19 antibodies and outcomes among outpatient maintenance hemodialysis patients. Kidney360. 2021;2(2):263–9.

    Article  PubMed  Google Scholar 

  209. Hsu CM, Weiner DE. COVID-19 in dialysis patients: outlasting and outsmarting a pandemic. Kidney Int. 2020;98(6):1402–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  210. Meller ME, Pfaff BL, Borgert AJ, Richmond CS, et al. Optimized infection control practices augment the robust protective effect of vaccination for ESRD patients during a hemodialysis facility SARS-CoV-2 outbreak. Am J Infect Control. 2022;50(10):1118–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  211. Petrilli CM, Jones SA, Yang J, Rajagopalan H, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.

    Article  PubMed  PubMed Central  Google Scholar 

  212. Flythe JE, Assimon MM, Tugman MJ, Chang EH, et al. Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States. Am J Kidney Dis. 2021;77(2):190–203 e1.

    Article  CAS  PubMed  Google Scholar 

  213. Hsu CM, Weiner DE, Aweh G, Miskulin DC, et al. COVID-19 among US dialysis patients: risk factors and outcomes from a National Dialysis Provider. Am J Kidney Dis. 2021;77(5):748–756 e1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  214. Caplin B, Ashby D, McCafferty K, Hull R, et al. Risk of COVID-19 disease, dialysis unit attributes, and infection control strategy among London in-center hemodialysis patients. Clin J Am Soc Nephrol. 2021;16(8):1237–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  215. Centers for Disease Control and Prevention. Infection control guidance for healthcare professionals about Coronavirus (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control.html. Accessed 23 Dec 2022.

  216. Mahallawi WH, Ibrahim NA, Mumena WA. Effectiveness of COVID-19 vaccines in patients under maintenance hemodialysis. Risk Manag Healthc Policy. 2021;14:5081–8.

    Article  PubMed  PubMed Central  Google Scholar 

  217. El Karoui K, Hourmant M, Ayav C, Glowacki F, et al. Vaccination and COVID-19 dynamics in dialysis patients. Clin J Am Soc Nephrol. 2022;17(3):395–402.

    Article  PubMed  PubMed Central  Google Scholar 

  218. Ashby DR, Caplin B, Corbett RW, Asgari E, et al. Severity of COVID-19 after vaccination among hemodialysis patients: an observational cohort study. Clin J Am Soc Nephrol. 2022;17(6):843–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  219. Kallen AJ, Arduino MJ, Patel PR. Preventing infections in patients undergoing hemodialysis. Expert Rev Anti-Infect Ther. 2010;8(6):643–55.

    Article  PubMed  Google Scholar 

  220. Hess S, Bren V. Essential components of an infection prevention program for outpatient hemodialysis centers. Semin Dial. 2013;26(4):384–98.

    Article  PubMed  Google Scholar 

  221. U.S. Department of Health and Human Services, Viral Hepatitis National Strategic Plan for the United States: a roadmap to elimination (2021–2025). 2020.

    Google Scholar 

Download references

Acknowledgments

The authors extend their gratitude to Danae Bixler, Stephanie Booth, Anne Moorman and Rebekah Stewart for providing their knowledge and expertise to this chapter.

Author information

Authors and Affiliations

  1. Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA

    Ibironke W. Apata, Matthew J. Arduino & Shannon Novosad

  2. Division of Renal Medicine, Emory University School of Medicine, Atlanta, GA, USA

    Ibironke W. Apata

Authors
  1. Ibironke W. Apata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew J. Arduino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shannon Novosad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ibironke W. Apata .

Editor information

Editors and Affiliations

  1. Section of Nephrology, Baylor College of Medicine, Houston, TX, USA

    Stephen Z. Fadem

  2. Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brazil

    José A. Moura-Neto

  3. Salisbury, VT, USA

    Thomas A. Golper

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Apata, I.W., Arduino, M.J., Novosad, S. (2023). Hemodialysis Infectious Complications. In: Fadem, S.Z., Moura-Neto, J.A., Golper, T.A. (eds) Complications in Dialysis. Springer, Cham. https://doi.org/10.1007/978-3-031-44557-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-44557-6_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-44556-9

  • Online ISBN: 978-3-031-44557-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation